Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial.

Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD.

JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3394. [Epub ahead of print]

PMID:
31580386
2.

An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.

Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G.

Oncologist. 2019 Aug 7. pii: theoncologist.2018-0905. doi: 10.1634/theoncologist.2018-0905. [Epub ahead of print]

PMID:
31391296
3.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.

4.

Use of Precision Imaging in the Evaluation of Pancreas Cancer.

Korn RL, Rahmanuddin S, Borazanci E.

Cancer Treat Res. 2019;178:209-236. doi: 10.1007/978-3-030-16391-4_8.

PMID:
31209847
5.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.

PMID:
31126960
6.

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.

Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ.

JAMA Oncol. 2019 Jul 1;5(7):993-998. doi: 10.1001/jamaoncol.2019.0684.

PMID:
31120501
7.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T.

Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.

8.

Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.

Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N.

Cancer. 2019 Jul 15;125(14):2488-2496. doi: 10.1002/cncr.32077. Epub 2019 Apr 12.

PMID:
30980401
9.

Neo-adjuvant therapy for pancreatic cancer: hope for the future.

Borazanci E, Sckolnik S, Amini A.

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):579-589. doi: 10.1080/17474124.2019.1607294. Epub 2019 May 2.

PMID:
30979348
10.

Triptolide and Its Derivatives as Cancer Therapies.

Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H.

Trends Pharmacol Sci. 2019 May;40(5):327-341. doi: 10.1016/j.tips.2019.03.002. Epub 2019 Apr 8. Review.

PMID:
30975442
11.

Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.

Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB, Stobie L, Bahary N, Zeh H, Zureikat A, Hogg M, Lee K, Tsung A, Rhee J, Ohr J, Sun W, Lee J, Moser AJ, DeLeonardis K, Krejdovsky J, Dalton E, LaDuca H, Dolinsky J, Colvin A, Lim C, Black MH, Tung N.

Cancer. 2018 Sep 1;124(17):3520-3527. doi: 10.1002/cncr.31628. Epub 2018 Aug 1.

12.

Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".

Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DD.

Clin Cancer Res. 2017 Apr 1;23(7):1629-1637. doi: 10.1158/1078-0432.CCR-16-2070. Review.

13.

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.

Borazanci E, Millis SZ, Kimbrough J, Doll N, Von Hoff D, Ramanathan RK.

J Gastrointest Oncol. 2017 Feb;8(1):164-172. doi: 10.21037/jgo.2017.01.14.

14.

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Borazanci E, Millis SZ, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, Cridebring D, Von Hoff DD.

World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40. doi: 10.4251/wjgo.v7.i9.132. Review.

15.

Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.

Borazanci E, Von Hoff DD.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):739-47. doi: 10.1586/17474124.2014.925799. Epub 2014 May 31. Review.

PMID:
24882381
16.

Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells.

Davis JN, Rogers D, Adams L, Yong T, Jung JS, Cheng B, Fennell K, Borazanci E, Moustafa YW, Sun A, Shi R, Glass J, Mathis JM, Williams BJ, Meyers S.

J Cell Physiol. 2010 Nov;225(3):875-87. doi: 10.1002/jcp.22298.

PMID:
20607802
17.

RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region.

Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S.

J Cell Biochem. 2006 Jan 1;97(1):1-17.

PMID:
16237704

Supplemental Content

Loading ...
Support Center